Compare Stocks: VXRT, PFNX, CGC, and AVIR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.13 +0.6%	$5.23	$2.81 ▼ $6.45	$411.45M	0.39	295,226 shs	253,264 shs
CGC Canopy Growth	$0.88 -0.8%	$0.96	$0.84 ▼ $2.38	$393.32M	0.78	2.10 million shs	2.04 million shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
VXRT Vaxart	$0.44 -0.7%	$0.50	$0.31 ▼ $0.84	$106.50M	1.05	245,345 shs	239,377 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-0.77%	-11.86%	+3.01%	+78.13%
CGC Canopy Growth	0.00%	-7.02%	-10.02%	-12.46%	-36.57%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
VXRT Vaxart	0.00%	-3.93%	-11.27%	-31.72%	+15.61%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AVIR Atea Pharmaceuticals	$5.13 +0.6%	$5.23	$2.81 ▼ $6.45	$411.45M	0.39	295,226 shs	253,264 shs
CGC Canopy Growth	$0.88 -0.8%	$0.96	$0.84 ▼ $2.38	$393.32M	0.78	2.10 million shs	2.04 million shs
PFNX Pfenex	$12.75	$12.75	$5.26 ▼ $14.00	$437.29M	N/A	503,865 shs	N/A
VXRT Vaxart	$0.44 -0.7%	$0.50	$0.31 ▼ $0.84	$106.50M	1.05	245,345 shs	239,377 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AVIR Atea Pharmaceuticals	0.00%	-0.77%	-11.86%	+3.01%	+78.13%
CGC Canopy Growth	0.00%	-7.02%	-10.02%	-12.46%	-36.57%
PFNX Pfenex	0.00%	0.00%	0.00%	0.00%	0.00%
VXRT Vaxart	0.00%	-3.93%	-11.27%	-31.72%	+15.61%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AVIR Atea Pharmaceuticals	2.33	Hold	$7.00	36.45% Upside
CGC Canopy Growth	2.20	Hold	N/A	N/A
PFNX Pfenex	0.00	N/A	N/A	N/A
VXRT Vaxart	2.00	Hold	N/A	N/A

Current Analyst Ratings Breakdown

Latest VXRT, PFNX, CGC, and AVIR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/2/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/16/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/13/2026	AVIR Atea Pharmaceuticals	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$6.00 ➝ $7.00
8/12/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	AVIR Atea Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/14/2026	CGC Canopy Growth	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/9/2026	VXRT Vaxart	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold

(Data available from 10/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	$3.53 per share	N/A
CGC Canopy Growth	$251.01M	1.57	N/A	N/A	$1.13 per share	0.77
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	$237.26M	0.45	$0.10 per share	4.27	$0.37 per share	1.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AVIR Atea Pharmaceuticals	-$158.35M	-$2.08	N/A	N/A	N/A	N/A	-64.25%	-57.12%	11/11/2026 (Estimated)
CGC Canopy Growth	-$190.29M	-$0.45	N/A	N/A	N/A	-65.33%	-21.91%	-14.34%	11/6/2026 (Estimated)
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	$16.33M	$0.16	2.73	N/A	N/A	15.88%	53.04%	20.85%	11/12/2026 (Estimated)

Latest VXRT, PFNX, CGC, and AVIR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	AVIR Atea Pharmaceuticals	-$0.5550	-$0.41	+$0.1450	-$0.41	$33.03 million	N/A
8/7/2026	Q1 2027	CGC Canopy Growth	-$0.04	-$0.02	+$0.02	-$0.02	$58.21 million	$142.62 million
8/6/2026	Q2 2026	VXRT Vaxart	-$0.12	-$0.06	+$0.06	-$0.06	$26.21 million	$27.19 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AVIR Atea Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
CGC Canopy Growth	N/A	N/A	N/A	N/A	N/A
PFNX Pfenex	N/A	N/A	N/A	N/A	N/A
VXRT Vaxart	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AVIR Atea Pharmaceuticals	N/A	8.13	8.13
CGC Canopy Growth	0.31	3.04	2.39
PFNX Pfenex	N/A	N/A	N/A
VXRT Vaxart	N/A	1.60	1.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AVIR Atea Pharmaceuticals	86.67%
CGC Canopy Growth	3.33%
PFNX Pfenex	N/A
VXRT Vaxart	18.05%

Insider Ownership

Company	Insider Ownership
AVIR Atea Pharmaceuticals	21.60%
CGC Canopy Growth	0.35%
PFNX Pfenex	N/A
VXRT Vaxart	2.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AVIR Atea Pharmaceuticals	55	80.21 million	62.88 million	Optionable
CGC Canopy Growth	1,128	449.30 million	447.73 million	Optionable
PFNX Pfenex	71	34.30 million	N/A	Not Optionable
VXRT Vaxart	120	243.70 million	236.88 million	No Data

VXRT, PFNX, CGC, and AVIR Headlines

Recent News About These Companies

Vaxart (OTCMKTS:VXRT) Share Price Breaks Below 200-Day Moving Average - Here's Why

October 1 at 3:01 AM | americanbankingnews.com

Vaxart (OTCMKTS:VXRT) Share Price Passes Below Two Hundred Day Moving Average - What's Next?

September 23, 2026 | americanbankingnews.com

Vaxart Highlights Oral Vaccine Platform, COVID Trial Progress at H.C. Wainwright Conference

September 15, 2026 | marketbeat.com

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | finance.yahoo.com

Vaxart to Present at the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026 | globenewswire.com

Vaxart Secures New European Patent Covering Oral Norovirus Vaccine Technology

August 27, 2026 | finance.yahoo.com

Vaxart Expands Intellectual Property Portfolio with European Patent Protecting Proprietary Norovirus Vaccine Technology

August 26, 2026 | globenewswire.com

Vaxart Inc (VXRT) (Q2 2026) Earnings Call Highlights: Oral COVID Vaccine Shows Promise, Cash ...

August 10, 2026 | finance.yahoo.com

Vaxart outlines Phase IIb COVID-19 top line data in first half of 2027 backed by BARDA funding

August 8, 2026 | seekingalpha.com

Vaxart, Inc. (VXRT) Q2 2026 Earnings Call Transcript

August 7, 2026 | seekingalpha.com

Vaxart Provides Business Update and Reports Second Quarter 2026 Financial Results

August 6, 2026 | markets.businessinsider.com

Vaxart Q2 2026 earnings preview

August 5, 2026 | msn.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | finance.yahoo.com

Vaxart to Host Stockholder Fireside Chat on August 7 at 4:30 p.m. ET

July 30, 2026 | globenewswire.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | finance.yahoo.com

Vaxart to Participate in BTIG Biotechnology Conference 2026

July 21, 2026 | globenewswire.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | finance.yahoo.com

Vaxart Announces Results of Annual Meeting of Stockholders

July 17, 2026 | globenewswire.com

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

July 6, 2026 | finance.yahoo.com

Vaxart Reports Topline 12-Month Safety Data From the 400-Participant Sentinel Safety Cohort of the Phase 2b Clinical Trial of Its Oral Pill COVID-19 Vaccine

July 6, 2026 | globenewswire.com

Vaxart Enters Cooperation Agreement with Stockholder Group and Announces Board and Corporate Governance Enhancements

July 1, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, PFNX, CGC, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

$5.13 +0.03 (+0.59%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$5.25 +0.12 (+2.34%)

As of 10/2/2026 07:30 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

Canopy Growth NASDAQ:CGC

$0.88 -0.01 (-0.79%)

Closing price 10/2/2026 04:00 PM Eastern

Extended Trading

$0.88 +0.00 (+0.53%)

As of 10/2/2026 07:58 PM Eastern

Canopy Growth Corporation, together with its subsidiaries, engages in the production, distribution, and sale of cannabis and hemp-based products for recreational and medical purposes primarily in the United States, Canada, Germany, and internationally. It operates through Canada Cannabis, International Markets Cannabis, and Storz & Bickel segments. The company offers dried flower, pre-rolled joints, oils, softgel capsules, infused beverages, edibles comprising gummies, and topical formats, as well as vaporizer devices. It sells its products under the Tweed, 7ACRES, DOJA, Deep Space, HiWay, Maitri, Twd., Vert, Spectrum Therapeutics, Canopy Medical, Storz & Bickel, Martha Stewart, and Wana brands. The company was formerly known as Tweed Marijuana Inc. and changed its name to Canopy Growth Corporation in September 2015. Canopy Growth Corporation was incorporated in 2009 and is headquartered in Smiths Falls, Canada.

Pfenex NYSEAMERICAN:PFNX

$12.75 0.00 (0.00%)

As of 10/1/2020

Pfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.

Vaxart OTCMKTS:VXRT

$0.44 0.00 (-0.68%)

As of 10/2/2026 03:59 PM Eastern

Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VXRT, PFNX, CGC, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VXRT, PFNX, CGC, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VXRT, PFNX, CGC, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, PFNX, CGC, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Canopy Growth NASDAQ:CGC

Pfenex NYSEAMERICAN:PFNX

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest VXRT, PFNX, CGC, and AVIR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest VXRT, PFNX, CGC, and AVIR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

VXRT, PFNX, CGC, and AVIR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

VXRT, PFNX, CGC, and AVIR Company Descriptions

Atea Pharmaceuticals NASDAQ:AVIR

Canopy Growth NASDAQ:CGC

Pfenex NYSEAMERICAN:PFNX

Vaxart OTCMKTS:VXRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools